• Skip to primary navigation
  • Skip to main content
miradx

MiraDx

We use our unique microRNA-based biomarkers to personalize cancer treatments and drug development.

  • Tests +
    • PROSTOXTM
    • PrevIOTOX
    • KRAS-Variant
    • AT
    • COVID-19
      • Order PCR Tests Online
      • COVID-19 Testing for Organizations
  • Pipeline
  • Partnering
  • About +
    • About MiraDx
    • Press
  • News
  • Contact

PROSTOXTM

TESTS

PROSTOXTM

Our First Radiogenomics Assay — PROSTOX

The PROSTOX test helps prostate cancer patients avoid toxicity from radiation therapy.

Our first microRNA-based radiogenomics assay is for prostate cancer patients who are being offered stereotactic body radiation therapy (SBRT).

The PROSTOX test analyzes the patient's germline DNA to determine if the individual is at increased risk of late grade ≥2 genitourinary (GU) toxicity following radiation therapy.

PROSTOX reports the risk of late GU radiation toxicity based on their mirSNP signature. The assay provides a risk score (low or high) that may be useful to help identify the safest course of treatment to avoid toxicity in the management of their prostate cancer.

To learn more about PROSTOX:

DOWNLOAD PDF

Begin PROSTOX Testing

Would you like to join our clinics in using the PROSTOX test? Please contact us here to arrange a meeting.

Publications-Radiogenomics and Prostate Cancer

  1. Kishan AU, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Network Open 2019;2:e188006.
  2. Weidhaas, JB, et al. MicroRNA-based biomarkers of the radiation response in prostate cancer. Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 163-163. DOI: 10.1200/JCO.2020.38.6_suppl.163.
  3. Kishan AU, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Journal for Radiotherapy and Oncology 2022;167:226-232. doi: 10.1016/j.radonc.2021.12.040.

Test Ordering Links

  • KRAS-variant Test for Individuals
  • KRAS-variant Test Ordering for Clinicians
  • ImuDx Test Ordering for Clinicians
  • Ataxia Telangiectasia (AT) Test Ordering for Clinicians

Information

  • Privacy Policy
  • Financial Conflict of Interest Policy
  • MiraDX CLIA certification #: 07D2006340

Contact Us

424-387-8100

info@miradx.com

CLIA Lab Address:

11600 Wilshire Blvd., Suite 410, Los Angeles, CA, 90025

Administrative Address:

11601 Wilshire Blvd., Suite 2410, Los Angeles, CA, 90025

MiraDx © Copyright 2023. All Rights Reserved. Website by RC Vane